Monoaminergic challenge tests allow investigating central nervous changes in humans under acute depletion of specific neurotransmitters (5-HT, DA, NE). Along with studies using alpha-methyl-para-tyrosine test (AMPT) and phenylalanine/tyrosine depletion test (APTD), the tryptophan depletion test (ATDT) represents the currently most established human challenge tool for the assessment of brain serotonin functioning. Neurophysiological studies in healthy and clinical samples may contribute to the search for a non-invasive and reliable biological marker of monoaminergic vulnerability or dysfunction. In the design of these studies, various biochemical and methodological aspects have to be taken into account. This article focuses on electrophysiological methodology and results of monoamine depletion studies (i.e., electroencephalography, magnetoencephalography, polysomnography, auditory evoked potentials and startle response).
Van PraagHMAsnisGMKahnRSBrownSLKornMFriedmanJMWetzlerS. Nosological tunnel vision in biological psychiatry: A plea for a functional psychopathology. Ann NY Acad Sci1990; 600: 501–510.
2.
BooijLVan der DoesAJRiedelWJ. Monoamine depletion in psychiatric and healthy populations: Review. Mol Psychiatry2003; 8: 951–973.
3.
BiggioGFaddaFFanniPTagliamonteAGessaGL. Rapid depletion of serum tryptophan, brain tryptophan, serotonin and 5-hydroxyindoleacetic acid by a tryptophan-free diet. Life Sci1974; 14: 1321–1329.
4.
DelgadoPLCharneyDSPriceLHAghajanianGKLandisHHeningerGR. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry1990; 47:411–418.
5.
YoungSNErvinFRPihlROFinnP. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology1989; 98: 508–511.
6.
BenkelfatCEllenbogenMADeanPPalmourRMYoungSN. Mood-lowering effect of tryptophan depletion: Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry1994; 51: 687–697.
7.
CarpenterLLAndersonGMPeltonGHGudinJAKirwinPDPriceLH. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology1998; 19:26–35.
8.
BaumannMHAyestasMARothmanRB. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats. J Neurosci1998; 18: 9069–9077.
9.
BremnerJDInnisRBSalomonRMStaibLHNgCKMillerHL. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry1997; 54: 364–374.
10.
NishizawaSBenkelfatCYoungSNLeytonMMzengezaSDe MontignyC. Differences between males and females in rates of serotonin synthesis in human brain. Proc Nat Acad Sci USA1997; 94: 5308–5313.
11.
NeumeisterANugentACWaldeckTGeraciMSchwarzMBonneO. Neuronal and behavorial responses to tryptophan depletion in unmedicated patients with major depressive disorder and healthy controlsArch Gen Psychiatry2004; 61:765–773.
12.
KnottVJHowsonALPeruginiMRavindranAVYoungSN. The effect of acute tryptophan depletion and fenfluramine on quantitative EEG and mood in healthy male subjects. Biol Psychiatry1999; 46: 221–228.
13.
HughesJHAshtonCHMatthewsDYoungAH. Acute depletion of plasma tryptophan does not alter electrophysiological variables in healthy males. Psychophamacol2000; 152:119–121.
14.
PhillipsMLangleyRWBradshawCMSzabadiE. The effects of some antidepressant drugs on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man. J Psychopharmacol (2000); 14: 40–45.
15.
YoungAHHughesJHMarshVRAshtonCH. Acute tryptophan depletion attenuates auditory event related potentials in bipolar disorder: A preliminary study. J Affect Disord2002; 69: 83–92.
16.
BhattiTGillinJCSeifritzEMoorePClarkCGolshanS. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry1998; 43:52–59.
17.
VoderholzerUHornyakMThielBHuwig-PoppeCKiemenAKonigA. Impact of experimentally induced serotonin deficiency by tryptophan depletion on sleep EEG in healthy subjects. Neuropsychopharmacology1998; 18:112–124.
18.
MoorePGillinCBhattiTDe ModenaASeifritzEClarkC. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry1998; 55: 534–539.
19.
EvansLGolshanSKelsoeJRapaportMResovskyKSuttonLGillinJC. Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion. Neuropsychopharmacology2002; 27:1016–1026.
20.
HaynesPLMcQuaidJRKelsoeJRapaportMGillinJC. Affective state and EEG sleep profile in response to rapid tryptophan depletion in recently recovered nonmedicated depressed individuals. J Affect Disord2004; 83: 253–262.
21.
LandoltHPKelsoeJRRapaportMHGillinJC. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. J Sleep Res.2003; 12:13–18.
22.
RiemannDFeigeBHornyakMKochSHohagenFVoderholzerU. The tryptophan depletion test: Impact on sleep in primary insomnia — a pilot study. Psychiatry Res2002; 109:129–135.
23.
LewisDACampbellMJFooteSLMorrisonJH. The monoaminergic innervation of primate neocortex. Hum Neurobiol1986; 5:181–188.
24.
JacobsBLAzmitiaEC. Structure and function of the brain serotonin system. Physiol Rev1992; 72:165–229.
25.
HegerlUJuckelG. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis. Biol Psychiatry1993; 33:173–187.
26.
EhlersCLWallTLChaplinRL. Long latency event-related potentials in rats: Effects of dopaminergic and serotonergic depletions. Pharmacol Biochem Behav1991; 38: 789–793.
27.
von KnorringLPerrisC. Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology1981; 7:1–8.
28.
PinedaJAHolmesTCFooteSL. Intensity-amplitude relationships in monkey event-related potentials: Parallels to human augmenting-reducing responses. Electroencephalogr Clin Neurophysiol1991; 78: 456–465.
29.
JuckelGHegerlUMolnárMCsépeVKarmosG. Auditory evoked potentials reflect serotonergic neuronal activity — a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology1999; 21: 710–716.
30.
SchergMVon CramonD. Two bilateral sources of the late AEP as identified by a spatio-temporal dipole model. Electroencephalogr Clin Neurophysiol1985; 62: 32–44.
31.
GallinatJBottlenderRJuckelGMunke-PuchnerAStotzGKussHJ. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI esponse in depression. Psychopharmacology2000; 48: 404–411.
32.
WangWTimsit-BerthierMSchoenenJ. Intensity dependence of auditory evoked potentials is pronounced in migraine: An indication of cortical potentiation and low serotonergic neurotransmission?Neurology1996; 46:1404–1409.
33.
HegerlUJuckelGSchmidtLGRommelspacherH. Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Psychiatry Res1996; 63: 47–55.
34.
TuchtenhagenFDaumannJNorraCGobbeleRBeckerSPelzS. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology2000; 22: 608–671.
35.
JuckelGGallinatJRiedelMSokulluSSchulzCMollerHJ. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. Schizophr Res2003; 64:115–124.
36.
NorraCMrazekMTuchtenhagenFGobbeléRBuchnerHSaßHHerpertzS. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiat Res2003; 37: 23–33.
37.
BuchsbaumMGoodwinFMurphyDBorgeG. AER in affective disorders. Am J Psychiatry1971; 128:19–25.
PogarellOJuckelGTatschKNorraCMüller-SiechenderFMulertC. Auditory evoked potentials and 1231-b-CIT-SPECT as predictors of the differential response to serotonergic versus noradrenergic antidepressants. Pharmacopsychiatry2003; 36: S253.
40.
JuckelGMavrogiorgouPBredemaierSGallinatJFrodlTSchulzC. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders — a retrospective study. Pharmacopsychiatry2004; 37:46–51.
41.
LinkaTMullerBWBenderSSartoryG. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett2004; 367: 375–378.
42.
LeeTWYuYWChenTJTsaiSJ. Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. J Psychiatry Neurosci2005; 30: 202–205.
43.
DierksTBartaSDemischLSchmeckKEnglertEKewitzA. Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: Effects of tryptophan depletion in healthy subjects. Psychopharmacology1999; 146:101–107.
44.
PhillipsMOxtobyEKLangleyRWBradshawCMSzabadiE. Effects of acute tryptophan depletion on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man. J Psychopharmacol2000; 14: 258–265.
45.
MasseyAEMarshVRMcAllister-WilliamsRH. Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. Biol Psychol2004; 65:137–145.
46.
DebenerSStrobelAKurschnerKKranziochCHebenstreitJMaerckerA. Is auditory evoked potential augmentation/reducing affected by acute tryptophan depletion?Biol Psychol2002; 59:121–133.
47.
NorraCBeckerSBroechelerAVreemannSKawohlWSassHBuchnerH. Electrophysiological effects of acute tryptophan depletion on human serotonergic functions. Clin EEG Neurosci2005; 36: 217.
48.
McAllister-WilliamsRHMasseyAERuggMD. Effects of tryptophan depletion on brain potential correlates of episodic memory retrieval. Psychopharmacology2002; 160: 434–442.
49.
KahkonenSJaaskelainenIPPennanenSLiesivuoriJAhveninenJ. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. Psychopharmacology2002; 164: 221–227.
50.
JuckelGSchmidtLGRommelspacherHHegerlU. The Tridimensional Personality Questionnaire and the intensity dependence of auditory evoked dipole source activity. Biol Psychiatry1995; 37: 311–317.
51.
PogarellOTatschKJuckelGHamannCMulertCPopperlG. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology2004; 29:1910–1917.
52.
O'NeillBVCraftRJLeungSGuilleVGallowayMPhanKLNathanPJ. Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans. Psychopharmacology2006; 188: 92–99.
53.
MöllerONorraCGründerG: Monoaminergic function in major depression: A possibly helpful tool for choosing treatment strategy (In German). Nervenarzt2006; 77: 800–808.
54.
NathanPJSegraveRPhanKLO'NeillBCroftRJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Hum Psychopharmacol2006; 21: 47–52.
55.
UhlIGoryniaIGallinatJMulertCWutzlerAHeinzAJuckelG. Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects?Hum Psychopharmacol2006; 21: 463–471.
56.
KahkonenSAhveninenJPennanenSLiesivuoriJLlmoniemiRJJaaskelainenIP. Serotonin modulates early cortical auditory processing in healthy subjects: Evidence from MEG with acute tryptophan depletion. Neuropsychopharmacology2002; 27: 862–868.
57.
NäätänenRTederWAlhoKLavikainenJ. Auditory attention and selective input modulation: A topographical ERP study. Neuroreport1992; 3: 493–496.
58.
AhveninenJKahkonenSPennanenSLiesivuoriJLlmoniemiRJJaaskelainenIP. Tryptophan depletion effects on EEG and MEG responses suggest serotonergic modulation of auditory involuntary attention in humans. Neuroimage2002; 16: 1052–1061.
59.
KahkonenSMakinenVJaaskelainenIPPennanenSLiesivuoriJAhveninenJ. Serotonergic modulation of mismatch negativity. Psychiatry Res2005; 138: 61–74.
60.
AhveninenJJaaskelainenIPPennanenSLiesivuoriJLlmoniemiRJKahkonenS. Auditory selective attention modulated by tryptophan depletion in humans. Neurosci Let2003; 340: 181–184.
61.
KochM. The neurobiology of startle. Progress Neurobiol1999; 59: 107–128.
62.
GeyerMAKrebs-ThomsonKBraffDLSwerdlowNR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology2001; 156: 117–154.
63.
SipesTAGeyerMA. Multiple serotonin subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology1994; 33: 441–448.
64.
FletcherPJSelhiZFAzampanahASillsTL. Reduced brain serotonin activity disrupts prepulse inhibition of the acoustic startle reflex: Effects of 5,7-dihydroxytryptamine and p-chlorophenylalanine. Neuropsychopharmacology2001; 24: 399–409.
65.
KehneJHPadichRAMcCloskeyTCTaylorVLSchmidtCJ. 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology1996; 124: 95–106.
66.
WaltersJKDavisMSheardMH. Tryptophan-free diet: Effects on the acoustic startle reflex in rats. Psychopharmacology1979; 62:103–109.
67.
NorraCBeckerSBrochelerAVreemannSHerpertzSSassH. Acoustic startle modulation by acute tryptophan depletion in healthy females. Int J Neuropsychopharmacol2002; 5: S194.
68.
Gouzoulis-MayfrankEHeekerenKThelenBLindenblattHKovarKASassHGeyerMA. The hallucinogen psilocybin increases prepulse inhibition of the startle reflex in the healthy humans. Behav Pharmacol1998; 9: 561–566.
69.
VollenweiderFXRemensbergerSHellDGeyerMA. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology1999; 143: 365–372.
70.
LiechtiMEGeyerMAHellDVollenweiderFX. Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology2001; 24: 240–252.
71.
QuednowBBKühnK-UStelzenmuellerRHoenigKMaierWWagnerM. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology2004; 175: 399–405.
72.
SjoerdsmaAEngelmanKSpectorS. Inhibition of catecholamine synthesis in man with a-methyl-paratyrosine, an inhibitor of tyrosine hydroxylase. Lancet1965; 2:1092–1094.
73.
BremnerJDVythilingamMNgCKVermettenENazeerAOrenDA. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: Implications for the neural circuitry of depression. JAMA2003; 289: 3125–3134.
74.
DelgadoPLMorenoFAOnateLGelenbergAJ. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol2002; 5: 63–66.
75.
NeumeisterATurnerEHMatthewsJRPostolacheTTBarnettRLRauhM. Effects of tryptophan depletion vs. catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry1998; 55: 524–530.
76.
AnandADarnellAMillerHLBermanRMCappielloAOrenDA. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry1999; 45: 972–978.
77.
VorugantiLSlomkaPZabelPCostaGSoAMattarAAwadAG. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology.2001; 25: 642–650.
78.
LeppavuoriA. The effects of an alpha-adrenergic agonist or antagonist on sleep during blockade of catecholamine synthesis in the cat. Brain Res1980; 193:117–128.
79.
RondouinGBaldy-MoulinierMPassouantP. The influence of hippocampal kindling on sleep organization in cats: Effects of alpha-methylparatyrosine. Brain Res1980; 181: 413–424.
80.
McCannUDThorneDHallMPoppKAveryWSingH. The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Neuropsychopharmacology1995; 13: 41–52.
81.
SalomonRMMillerHLKrystalJHHenningerGRCharneyDS. Lack of behavioral effects of monoamine depletion in healthy subjects. Biol Psychiatry1997; 41: 58–64.
82.
BiggioGPorcedduMLGessaGL. Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-30, 50-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine. J Neurochem1976; 26:1253–1255.
83.
MontgomeryAJMcTavishSFCowenPJGrasbyPM. Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: An [11C]raclopride PET study. Am J Psychiatry2003; 160:1887–1889.
84.
LeytonMDagherABoileauICaseyKBakerGBDiksicM. Decreasing amphetamine-induced dopamine release by acute phenylalanine / tyrosine depletion: A PET/[11C]raclo-pride study in healthy men. Neuropsychopharmacology2004; 29:427–432.
85.
LeytonMYoungSNBlierPBakerGBPihlROBenkelfatC. A comparison of the effects of acute tryptophan depletion and acute phenylalanine/tyrosine depletion in healthy women. Adv Exp Med Biol1999; 46: 767–771.
86.
HarrisonBJOlverJSNormanTRNathanPJ. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Hum Neuropsychopharmacol2002; 17: 293–297.
87.
RoiserJPMcLeanAOgilvieADBlackwellADBamberDJGoodyerI. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology2005; 30: 775–785.
88.
HealyDMcMonagleT. The enhancement of social functioning as atherapeutic principle in the management of depression. J. Psychopharmacol1997; 11(4suppl): S25–31.
